1-3 of 3
Ingrid Kuhn, MD
Close
Sort by
Journal Articles

Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Zdenek Adam, MD, Elena Tóthová, MD, Roman Hajek, MD, Boris Labar, MD, PhD, Miklós Egyed, MD, PhD, Ivan Spicka, MD, Johannes Drach, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Niklas Zojer, MD, Zoran Birovljev, Axel Hinke, PhD
Journal: Blood
Blood (2009) 114 (22): 2891.
https://doi.org/10.1182/blood.V114.22.2891.2891
Published: 2009
Journal Articles

Double Transplantation with Melphalan (200 mg/m 2 ) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma

Heinz Ludwig, MD, Ivan Spicka, MD, Werner Linkesch, MD, Richard Greil, Hedwig Kasparu, MD, Eberhard Gunsilius, MD, Josef Thaler, MD, Johannes Drach, MD, Ingrid Kuhn, MD, Adalbert Weiβmann, MD, Axel Hinke, PhD
Journal: Blood
Blood (2008) 112 (11): 3317.
https://doi.org/10.1182/blood.V112.11.3317.3317
Published: 2008
Journal Articles

Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment and Thalidomide-Interferon vs. Interferon Maintenance Therapy in Elderly Patients with Multiple Myeloma.

Heinz Ludwig, MD, Elena Tothova, MD, Roman Hajek, MD, Johannes Drach, MD, Zdenek Adam, MD, Boris Labar, MD, Miklós Egyed, MD, Ivan Spicka, MD, Heinz Gisslinger, MD, Ingrid Kuhn, MD, Axel Hinke, PhD
Journal: Blood
Blood (2007) 110 (11): 529.
https://doi.org/10.1182/blood.V110.11.529.529
Published: 2007